147 related articles for article (PubMed ID: 32515802)
41. East meets West in COVID-19 therapeutics.
Wang S; Zeng X; Wang Y; Zhao Y; Chen W; Chen YZ
Pharmacol Res; 2020 Sep; 159():105008. PubMed ID: 32531323
[No Abstract] [Full Text] [Related]
42. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
Poulas K; Farsalinos K; Zanidis C
Front Immunol; 2020; 11():1373. PubMed ID: 32612613
[No Abstract] [Full Text] [Related]
43. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.
Taccone FS; Gorham J; Vincent JL
Lancet Respir Med; 2020 Jun; 8(6):539-541. PubMed ID: 32304640
[No Abstract] [Full Text] [Related]
44. Biggest COVID-19 trial tests repurposed drugs first.
Nat Biotechnol; 2020 May; 38(5):510. PubMed ID: 32393915
[No Abstract] [Full Text] [Related]
45. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
Wang Y; Chen L
Br J Pharmacol; 2020 Nov; 177(21):4995-4996. PubMed ID: 32424836
[No Abstract] [Full Text] [Related]
46. Chloroquine for COVID-19 Infection.
Moore N
Drug Saf; 2020 May; 43(5):393-394. PubMed ID: 32266694
[No Abstract] [Full Text] [Related]
47. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
[TBL] [Abstract][Full Text] [Related]
48. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.
Ingraham NE; Boulware D; Sparks MA; Schacker T; Benson B; Sparks JA; Murray T; Connett J; Chipman JG; Charles A; Tignanelli CJ
Crit Care; 2020 Apr; 24(1):182. PubMed ID: 32345336
[No Abstract] [Full Text] [Related]
49. β-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.
Manglik A; Wingler LM; Rockman HA; Lefkowitz RJ
Circulation; 2020 Jul; 142(4):318-320. PubMed ID: 32412788
[No Abstract] [Full Text] [Related]
50. Fight against novel coronavirus: A perspective of medicinal chemists.
Amin SA; Jha T
Eur J Med Chem; 2020 Sep; 201():112559. PubMed ID: 32563814
[TBL] [Abstract][Full Text] [Related]
51. Psychosis Treatment During COVID-19 Pandemic and the Potential Role of Phenothiazines: A Call for Research Studies.
Ruiz de Pellón Santamaría Á
J Clin Psychopharmacol; 2020; 40(6):641-642. PubMed ID: 33136928
[No Abstract] [Full Text] [Related]
52. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
53. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.
Rofeal M; El-Malek FA
Med Hypotheses; 2020 Oct; 143():109904. PubMed ID: 32502901
[TBL] [Abstract][Full Text] [Related]
54. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters.
Yuan S; Wang R; Chan JF; Zhang AJ; Cheng T; Chik KK; Ye ZW; Wang S; Lee AC; Jin L; Li H; Jin DY; Yuen KY; Sun H
Nat Microbiol; 2020 Nov; 5(11):1439-1448. PubMed ID: 33028965
[TBL] [Abstract][Full Text] [Related]
55. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
56. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
[TBL] [Abstract][Full Text] [Related]
57. Teaching Old Drugs New Tricks: Statins for COVID-19?
Fajgenbaum DC; Rader DJ
Cell Metab; 2020 Aug; 32(2):145-147. PubMed ID: 32755604
[TBL] [Abstract][Full Text] [Related]
58. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
59. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2.
Luan J; Lu Y; Gao S; Zhang L
J Infect; 2020 Aug; 81(2):318-356. PubMed ID: 32283163
[No Abstract] [Full Text] [Related]
60. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
